|Bid||82.28 x 800|
|Ask||0.00 x 1100|
|Day's Range||86.32 - 88.03|
|52 Week Range||68.84 - 117.56|
|Beta (3Y Monthly)||0.88|
|PE Ratio (TTM)||102.33|
|Earnings Date||Feb 4, 2019 - Feb 8, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||111.67|
NEW YORK, Feb. 14, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Medidata Solutions acquired Waltham-based Shyft Analytics in June, and plans to hire hundreds of employees with a move to downtown Boston.
Haemonetics Corp NYSE:HAEView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is low for HAE with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding HAE totaled $69 million. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Haemonetics' (HAE) year-over-year earnings growth in Q3 is backed by benefits from complexity reduction and investments along with strength in market demand and success from early launches.
Haemonetics (HAE) delivered earnings and revenue surprises of 6.78% and -1.14%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Braintree, Massachusetts-based company said it had net income of 35 cents. Earnings, adjusted for non-recurring costs and amortization costs, were 63 cents per share. The results ...
Financial release accessible online BRAINTREE, Mass. , Feb. 5, 2019 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE) announced that its third quarter and year-to-date fiscal 2019 results ended December ...
Today we are going to look at Haemonetics Corporation (NYSE:HAE) to see whether it might be an attractive investment prospect. Specifically, we're going to calculate its Return On Capital Employed Read More...
Haemonetics (HAE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Perrigo's (PRGO) shares rebound as the time to file an appeal against the Irish tax bill of $1.9 billion nears its deadline of Dec 28.
Small-caps and large-caps are wildly popular among investors; however, mid-cap stocks, such as Haemonetics Corporation (NYSE:HAE) with a market-capitalization of US$4.8b, rarely draw their attention. However, generally ignored mid-caps have Read More...
Perrigo (PRGO), in a SEC filing, reports a $1.9 billion tax bill from Irish revenue department related to its subsidiary, Elan Pharma.
BRAINTREE, Mass. , Dec. 20, 2018 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE) announced that the Company intends to publish third quarter fiscal 2019 financial results at 6:00 am EST on Tuesday, ...
Haemonetics Corp., a Braintree-based company that makes blood management devices and software, has announced plans to move its headquarters to Boston's Financial District in 2019. Haemonetics (NYSE: HAE) said Wednesday it has signed a 14-year lease for 62,000 square feet of space at 125 Summer St. Part of that space — around 20,000 square feet — is currently occupied by online fantasy sports company DraftKings Inc., which is moving its headquarters to 500 Boylston St./222 Berkeley St. in Back Bay. More than 200 Haemonetics employees will relocate to the new Boston office, the company said.
BRAINTREE, Mass. , Dec. 20, 2018 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that Chris Simon , President and CEO, will present at the 37 th Annual J.P. Morgan Healthcare Conference in ...
In the news release, Haemonetics Announces Headquarters Relocation To Boston, issued 19-Dec-2018 by Haemonetics Corporation over PR Newswire, we are advised by the company that the third paragraph, first sentence, should read "17-acre campus" rather than "40-acre campus" as originally issued inadvertently. BRAINTREE, Mass., Dec. 19, 2018 /PRNewswire/ -- Haemonetics Corporation (HAE), a global medical technology company focused on delivering innovative hematology solutions to drive better patient outcomes, announced today that the company will be relocating its global headquarters to downtown Boston from its current location in Braintree, Massachusetts.
Is Haemonetics Corporation (NYSE:HAE) a good investment right now? We check hedge fund and billionaire investor sentiment before delving into hours of research. Hedge funds spend millions of dollars on Ivy League graduates, expert networks, and get tips from industry insiders. They sometimes fail miserably but historically their consensus stock picks outperformed the market after […]
Haemonetics (HAE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.